Novo Nordisk A/S (NVO) advanced 2.12% as investors responded to ongoing share buybacks and recent FDA approval for its pediatric insulin product, with anticipation building ahead of the upcoming Q3 2026 earnings release. The rebound looks limited, with the stock still trading below its 50-day and 200-day moving averages and momentum signals showing persistent selling pressure.
Highlights
- Novo Nordisk has repurchased DKK 11.19 billion of its DKK 15 billion buyback program and secured FDA clearance for Awiqli insulin in pediatric type 2 diabetes.
- The company is set to report Q3 2026 earnings on November 4, with consensus at $0.7270 per share and $11.09 billion revenue while managing competitive and legal challenges in the GLP-1 sector.
- Shares of Novo Nordisk trade above short-term averages, but momentum and oscillators remain weak with a projected five-day range of $38.45 to $39.75 and strong downside probability.
Share buybacks and FDA win offset earnings focus and legal risks
Novo Nordisk is running an active share buyback program, having repurchased DKK 11.19 billion out of its targeted DKK 15 billion allocation, and recently received FDA clearance for Awiqli, a pediatric insulin product for children aged 10 and older with type 2 diabetes. The company is preparing to report Q3 2026 earnings on November 4, with consensus estimates at $0.7270 per share and $11.09 billion in revenue. Novo Nordisk is also navigating competitive pressure in the GLP-1 weight loss segment, as well as a legal dispute regarding advertising against Eli Lilly.
Short-term gains contrast with persistent selling and weak momentum
Novo Nordisk is trading above its 20-day moving average at $38.45, but remains below both the 50-day ($41.5) and 200-day ($44.39) averages. This pattern suggests the stock has regained some short-term momentum, yet medium- and long-term trends still show pressure from sellers, with resistance at $39.26 and immediate support at $38.54. Key momentum indicators remain weak: MACD and ADX highlight continued selling, while RSI at 40.63 is moderately bearish and signals mild oversold conditions. Stochastic RSI and CCI remain neutral, and BBP at -0.27 points to intraday dominance by sellers and further oversold signals. Despite intraday strength toward highs, negative momentum and oscillator readings diverge from price action.
Earlier, analysts noted that Novo Nordisk was experiencing persistent bearish momentum amid technical and competitive pressures. The current analysis reinforces this downside bias, with key resistance now shifting higher and a new trading range emerging, highlighting continued risk for further declines if the stock breaks below immediate support.